Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data
Viking Therapeutics (VKTX) Shares Rally On Strong Phase 2 Trial Data
Stock price for Viking Therapeutics, Inc. (NASDAQ: VKTX) jumped 111.23% this current session, reaching $81.28 – a promising sign. Recent favorable clinical outcomes correlate with this increase in VKTX stock price.
維京療法公司（納斯達克股票代碼：VKTX）的股價在本交易日上漲了111.23％，至81.28美元，這是一個令人鼓舞的跡象。最近良好的臨床結果與VKTX股價的上漲相關。
Viking Therapeutics (VKTX) disclosed encouraging Phase 2 trial findings for VK2735, a medication targeting GLP-1 and GIP receptors, aiming to tackle obesity and metabolic issues. The Phase 2 VENTURE trial has effectively met its primary objective along with all secondary goals, with subjects administered VK2735 demonstrating statistically significant declines in body mass compared to those on placebo.
Viking Therapeutics（VKTX）披露了令人鼓舞的 VK2735 二期試驗結果。是一種靶向 GLP-1 和 GIP 受體的藥物，旨在解決肥胖和代謝問題。2 期 VENTURE 試驗有效地實現了其主要目標和所有次要目標，與服用安慰劑的受試者相比，服用 VK2735 的受試者的體重有統計學上的顯著下降。
Furthermore, the study indicates that VK2735 treatment is well-tolerated and safe, with most treatment-related adverse events categorized as mild or moderate. Viking intends to engage with the FDA to discuss subsequent developmental steps for VK2735 based on these findings. Patients subjected to weekly VK2735 doses exhibited statistically notable reductions in average body mass after a 13-week regimen, ranging up to 14.7% from baseline.
此外，該研究表明，VK2735 治療耐受性良好且安全，大多數與治療相關的不良事件歸類爲輕度或中度。維京打算與美國食品藥品管理局合作，根據這些發現討論 VK2735 的後續開發步驟。每週接受 VK2735 劑量的患者在接受爲期 13 周的療程後，平均體重在統計學上顯著下降，與基線相比高達 14.7%。
These patients also displayed statistically significant declines in average body mass compared to the placebo group, reaching up to 13.1%. Significant differences relative to both baseline and placebo were evident across all dosages starting from the first week and persisting throughout the 13-week treatment period. Weight reduction exhibited a progressive trend during the study duration, with no plateau observed at the 13-week mark.
與安慰劑組相比，這些患者的平均體重也出現了統計學上的顯著下降，降至13.1％。從第一週開始，所有劑量與基線和安慰劑的顯著差異都很明顯，在整個13周的治療期內持續存在。在研究期間，體重減輕呈漸進趨勢，在13周時未觀察到停滯狀態。
All VK2735 dosage levels showcased statistically significant variances compared to placebo regarding the key secondary endpoint, which assessed the proportion of patients achieving at least a 10% weight reduction. Remarkably, up to 88% of patients in VK2735 treatment cohorts achieved this milestone, compared to a mere 4% for the placebo group. VK2735 demonstrated commendable safety and tolerability profiles following a 13-week regimen of once-weekly dosing.
與安慰劑相比，所有 VK2735 劑量水平在關鍵次要終點方面都顯示出統計學上的顯著差異，後者評估了體重減輕至少 10% 的患者比例。值得注意的是，在 VK2735 治療組中，多達 88% 的患者實現了這一里程碑，而安慰劑組的這一比例僅爲 4%。在爲期 13 周的每週給藥方案之後，VK2735 表現出值得稱道的安全性和耐受性。
Discontinuation rates in the VENTURE study remained low and evenly distributed between patients treated with VK2735 and those administered placebo. In total, 23 patients (13%) discontinued treatment during the study, with 5 (14%) in the placebo cohort and 18 (13%) among VK2735-treated cohorts.
VENTURE 研究中的停藥率仍然很低，並且在接受 VK2735 治療的患者和服用安慰劑的患者之間分佈均勻。在研究期間，共有23名患者（13％）停止治療，其中5名（14％）在安慰劑隊列中，18名（13％）在接受VK2735治療的隊列中。